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Case presentation
A 52-year-old man was referred to Leiden University Hospital for
management of acute renal insufficiency. Several previous yearly
medical examinations had demonstrated normal urinary sediment and
renal function. His medical history included an appendectomy 40 years
previously and the removal of a cyst in his neck 13 years previously. He
had traveled extensively in the Far East without contracting any
tropical diseases. One week before admission to a local hospital, he had
experienced malaise; 2 days later he voided reddish-brown and cloudy
urine. His temperature ranged between 38.5°C and 40.0°C, and he had
chills. Neither dysuria nor oliguria was present. He did not feel any pain
or discomfort in his lumbar region. Abdominal abnormalities and
arthralgia were absent. The local physician prescribed paracetamol!
codeine and trimethoprim/sulfamethoxazol for erythrocyturia.
On admission to the local hospital, the patient was severely ill; his
temperature was 39.2°C, and the pulse rate was 100/mm. No signs of
infection of the upper or lower respiratory tract were present. No
abnormalities were found in his chest, abdomen, or extremities. His
prostate was slightly enlarged. Laboratory investigation revealed a
urinary sediment with many erythrocytes and some leukocytes. The
serum creatinine concentration was 415 mollliter (4.7 mg/dl); serum
urea, 9.2 mMol/liter; hemoglobin, 7.7 mMol/liter with normal indices;
leukocytes, 8.6 x 109/liter; platelets, 176 >< 109/liter; sodium, 137
mMol/liter; potassium, 3.6 mMollliter; capillary blood gases were
normal; calcium, 2.07 mMol/liter; phosphate, 1.13 mMol/liter; alkaline
phosphatase, 81 U/liter (normal, up to 150 U/liter); liver function tests
were normal; and serum albumin, 29 g/liter. Ultrasonography revealed
two kidneys of normal size with accentuation of the renal cortex.
Two days later the patient was referred to our hospital. On admission
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he did not appear ill. His temperature was 37.7°C and blood pressure
was 140/90 mm Hg. No abnormalities were found on physical exami-
nation. His prostate was not enlarged or painful. Gross hematuria was
still present without oliguria. The urinary sediment contained red cell
casts and several leukocytes. Urinary excretion of creatinine was 15.7
mMol/24 hr; sodium, 20 mMol/24 hr; and protein, 0.5 g124 hr. The serum
creatinine concentration was 731 jsmol/liter (8.3 mg/dl); serum urea,
18.1 mMollliter; sodium, 140 mMollliter; potassium, 3.9 rnMol/liter;
calcium, 2.15 mMol/liter; phosphate, 1.52 mMol/liter; total serum
protein, 62 g/liter; and serum albumin, 36 g/liter. Liver function tests
were normal. Immunologic studies revealed a negative anti-GBM
antibody test by ELISA, negative anti-neutrophil cytoplasmic antibody
(ANCA) test by indirect immunofluorescence, elevated total comple-
ment activity (CH50), with normal Clq, C4, and C3 serum levels, and a
negative Clq-binding assay but a positive anti-IgA inhibition of binding
assay (60 Eq of AIgA/ml), no cryoglobulins, and normal levels of Ig
isotypes without paraproteins. No 1gM or IgG antibodies were found
against cytomegalovirus or Epstein-Barr virus, and no hepatitis-B
surface antigen was detected. IgG antibodies with a titer of 1:1024 were
found against herpes simplex virus, but 1gM antibodies were not found.
The antistreptolysine titer was 100 U/mi. Parasites were not detected in
his stools. His sinuses and lungs were radiologically normal. An
electrocardiogram disclosed a normal sinus rhythm.
Ultrasonography revealed two kidneys of normal size and no hydro-
nephrosis. A renal biopsy specimen contained 14 glomeruli and showed
an increase in mesangial cells and matrix with extracapillary prolifera-
tion (Fig. 1). The tubular lumina were filled with erythrocytes (Fig. 2).
Blood vessels and interstitium were normal. Immunofluorescence
showed mesangial deposits of IgA and C3.
The patient was treated with 1.5 mg of prednisone per kg of body
weight and 4 x 15 ml aluminum hydroxide gel daily. The serum
creatinine initially rose to 789 Mol/liter (8,9 mg/dl) but subsequently
decreased to 434 jsMoI/liter (4.9 mg/dl) one week after admission. Gross
hematuria persisted. The prednisone dose was tapered and remained at
60 mg at the time of discharge 10 days after admission.
One week later he visited the outpatient department. Gross hematuria
had disappeared but microscopic hematuria and leukocyturia still were
present. The serum creatinine had decreased further to 376 jsMollliter
(4.2 mg/dl). The prednisone dose was lowered to 30 mg daily. A few
days later he developed dysuria, and a urine culture grew> lO colonies
of E.coli/ml. He was treated with 750 mg of amoxycillin, three times
daily. The prednisone dose was changed to 40 mg every other day.
Two weeks later he had to be readmitted because he had chills and a
sudden rise in temperature to 40.0°C without dysuria. His blood
pressure was 120/55 mm Hg. Physical examination disclosed no abnor-
malities. Rectal examination revealed a normal prostate that was not
painful. The urinary sediment again was full of erythrocytes and
leukocytes. Both the urine and blood cultures were positive forE. coli.
He was treated with cefamandole and gentamicin. His temperature
returned to normal the next day. A urologist examined the prostate on
the third hospital day. Twenty minutes later, the patient had chills and
a temperature of 40.0°C. The systolic blood pressure fell to 90 mm Hg.
After plasma infusion, the blood pressure stabilized. A diagnosis of
prostatitis was made and his therapy was changed to cotrimoxazole for
6 weeks. An intravenous pyelogram showed a normal nephrographic
phase and no abnormalities of the ureters. Gallium-67 leukocyte scm-
tigraphy revealed no accumulation of leukocytes around the kidney or
bladder, His serum creatinine level did not change during the period of
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Fig. 1. Extracapillary proliferation observed in one glomerulus in the
biopsy specimen
sepsis and decreased steadily to 203 jMol/liter (2.3 mgldl) on discharge.
The calculated creatinine clearance was 46 mI/mm. After discharge
from the hospital, the patient recovered completely. His serum creati-
nine decreased further to 126 tMol/Iiter (1.4 mg/dl), and his urinary
sediment remains normal.
Discussion
DR. L. A. VAN Es (Professor of Medicine, Department of
Nephrology, Leiden University Hospital, Leiden, The Nether-
lands): This patient manifested some unusual aspects of IgA
nephropathy (IgAN) that deserve consideration before we
embark on a more general discussion of this entity. He pre-
sented with acute renal insufficiency accompanied by fever. His
blood pressure was consistently normal, so the possibility of
septic shock as the cause of the renal failure was unlikely.
Although the presence of a urinary tract infection was not
established at the referring hospital, antibiotic administration
produced clinical improvement and a lowering of his tempera-
ture. The serologic tests all were unrevealing, except for a
positive anti-IgA inhibition of binding assay, which indicates
the presence of macromolecular IgA, possibly IgA immune
complexes, in the circulation, This test is positive in IgAN but
not in other types of primary glomerulonephritis [1]. A renal
biopsy, obtained before the result of this test became available,
Fig. 2. Tubular lumina filled with erythrocytes observed diffusely in the
biopsy specimen.
revealed mild mesangial hypercellularity and an increase of
mesangial matrix. One glomerulus showed extracapillary pro-
liferation. The tubules were filled with red blood cells, but no
conspicuous abnormalities were apparent in the interstitium.
Tubulointerstitial nephritis was not present. Immunofluores-
cence studies revealed mesangial deposits of IgA and C3 but not
of IgG or 1gM. These findings established the diagnosis of
IgAN. In the absence of any clinical manifestations of systemic
lupus erythematosus, alcoholic liver disease, celiac disease,
ankylosing spondylitis, or any other disorder known to be
associated with glomerular IgA deposits, the diagnosis was
specified as primary IgAN. Available information from earlier
"regular checkups" documented that the patient did not have
microscopic hematuria previously. His serum creatinine varied
between 82—119 jxMollliter (0.9—1.3 mg/dl) during the previous 9
years, and his urinary sediment was normal repeatedly. The
presentation of IgAN with gross hematuria, oliguria, and an acute
reduction of GFR is associated with crescent formation on renal
biopsy in 79%—100% of patients 2]. Frequently, however, the
number of glomeruli with crescents is insufficient to account for
the severity of the renal failure. When renal insufficiency occurs,
therefore, it is generally attributed to acute tubular damage and
obstruction secondary to glomerular bleeding [31.
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Mesangial deposits Frequency(%)a
IgA
C3
Properdin
IgG
1gM
100
77—100
30—83
60—83
22—65
a Data summarized from Ref. 11.
Clinical events that are known to provoke the development of
IgAN were not evident in this patient. The fever and chills
suggest a preceding infection, as frequently occurs in IgAN.
The infections that frequently precede relapses of IgAN by a
few days usually affect the upper respiratory tract, but IgAN
occasionally has been described in association with hemor-
rhagic cystitis [4]. Today's patient could have had a urinary
tract infection; the urinary sediment contained erythrocytes and
leukocytes, but initial urinary cultures did not reveal significant
bacteriuria. The antibiotics previously prescribed by the gen-
eral physician could have prevented the bacterial growth in the
urine culture.
Several studies have shown that patients with rapidly pro-
gressive IgAN can benefit from treatment with high-dose cor-
ticosteroids. Patients whose creatinine clearance exceeds 70
mI/mm show the most significant improvement, even when
histologic alterations are moderate to severe [5]. Studies also
indicate that children treated with alternate-day prednisone
maintain their renal function, as compared with untreated
children [6]. In this study, almost all children treated with
corticosteroids had normal urinalyses at followup [61, as did the
adult we presented today. Similar results were obtained in
children treated for one year with prednisone and azathioprine
[7]. In the patient we are discussing, the corticosteroid dose was
tapered and discontinued over 4 months. Of course, what would
have happened if corticosteroids had not been given is impos-
sible to predict. It also is possible that his renal function would
have improved without treatment with corticosteroids. But we
can reasonably speculate that the corticosteroids might have
provoked the exacerbation of the prostatitis.
IgA nephropathy is the most common form of glomerulone-
phritis in countries where renal biopsies are performed fairly
routinely to diagnose asymptomatic hematuria. In fact, the
diagnosis cannot be made with certainty without a renal biopsy;
the mesangial deposition of IgA is the hallmark of IgAN [8]. The
histologic lesions can vary from almost normal glomeruli to
mesangial proliferative, focal, or diffuse proliferative glomeru-
lonephritis with or without crescent formation. On the basis of
binding of secretory component and the detection of J-chain in
the mesangial IgA deposits, it is generally accepted that at least
part of the deposited IgA is polymeric. Interestingly, the
deposited IgA belongs to the IgA1 subclass [9]. In contrast to
other conditions, few IgA2 deposits are found in glomeruli of
patients with IgAN. The IgA deposits are mainly localized in
the mesangium, but they can extend to the periphery of the
glomerular capillaries. The presence of deposits in the capillar-
ies usually correlates with the presence of proteinuria [10]. Of
the other immunoglobulins, IgG is most often encountered in
the deposits 1111. 1gM is found less frequently in the mesangium
Table 2. Activation of cornplernent of various species by IgA
IgA
C-activation
source C sourcea pa AP Reference
Mouse Human
Guinea pig
Mouse
— —
— +
— +
18
18
18
Mouse Mouse — + 13
Human Human — + 14
Human Human — + 15
Rat Rat
Human
Guinea pig
— +
— —
— —
17
17
17
Mouse Rat — 17
= classical pathway; AP = alternative
(Table 1). The deposits of IgA frequently are accompanied by
deposits of C3 and other complement components of the
alternative pathway such as properdin; components of the
classical pathway usually are absent. The deposition of the
terminal complement sequence, the so-called membrane attack
complex (MAC), appears to correlate with progressive renal
failure [121.
IgA and complement activation
The capacity of IgA antibodies to activate complement has
been a controversial topic. It has generally been assumed that
complement components from various species are capable of
interacting with each other. Studies based on this assumption
have shown that IgA antibodies are unable to activate the
complement system (Table 2). However, the studies using
complement homologous to the IgA source—either mouse [13],
human [14, 151, or rat [16, 171—all show effective activation of
complement by the alternative pathway, but not by the classical
pathway. Various assays have been used to demonstrate com-
plement activation. Tests using erythrocytes either sensitized
or coated with IgA frequently have given negative results.
Studies using IgA aggregates prepared by chemical cross-
linking also have frequently been negative. However, immune
complexes and immune precipitates obtained by mixing antigen
and IgA antibodies at various molar ratios have yielded positive
results. In general, immune precipitates prepared at equiva-
lence have the highest activating potential [181. When mouse
monoclonal antibodies are used, mouse serum can be replaced
by guinea pig serum as a complement source, but not by human
serum (Table 2). IgA immune complexes prepared at equiva-
lence or in excess of mouse antibodies are solubilized by fresh
mouse serum [13]. Human IgA insolubilized on microwell
plates activates C3 via the alternative pathway [15]. Human
IgA1 and IgA2 do not differ in their capacity to activate the
alternative pathway; therefore the hinge region of IgA probably
is not involved in C3 activation. The F(abc)2 and F(ab)2
fragments of IgA are capable of activating the alternative
pathway, whereas F(ab)1 and Fc fragments are not [19].
Rat monoclonal antibodies also have been used to prepare
immune precipitates. Polymeric IgA (pIgA) antibodies are
significantly more efficient in forming insoluble immune com-
plexes than are monomeric IgA (mIgA) antibodies; this finding
Table 1. Frequency of Ig isotypes and complement detected by
immunofluorescence in mesangial deposits in IgA nephropathy
a C = complement; CP
pathway.
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Table 3. Reactivity of sera from patients with HSP or IgAN in the
a-IgA Inhib BA, a test that detects macromolecular IgA or IgA
immune complexesa
Whole 3% PEG
serum precipitat&' HSP IgAN
+ +
+
+
14
20
18
53
a HSP, Henoch-Schönlein purpura; a-IgA Inhib BA, inhibition of
binding assay; PEG, polyethyleneglycol.b Sera were tested before and after precipitation with 3% polyethyl-
eneglycol.
suggests a higher avidity of pIgA antibody [161. Immune pre-
cipitates prepared with either mIgA or pIgA antibodies activate
the alternative pathway efficiently. The solubilizing effect on
immune precipitates prepared with rat IgA antibodies can be
realized only with fresh rat serum as a complement source, and
not with fresh human or guinea pig serum [17]. However,
soluble immune complexes can activate the alternative pathway
only when pIgA antibodies (instead of mIgA antibodies) are
used [17].
Pfaffenbach et a! have suggested that activation of the alter-
native pathway by IgA antibodies usually does not proceed to
the terminal complement sequence C5—C9 [18]. The capacity of
the alternative pathway of complement to lyse red blood cells
was studied using trinitrophenol (TNP)-coated rat erythrocytes
and monomeric, dimeric (dIgA), and polymeric IgA anti-DNP
antibodies. The mIgA antibodies were unable to activate com-
plement, whereas pIgA antibodies were at least five times more
active than dIgA with respect to lysis of erythrocytes via the
alternative pathway [17].
These observations illustrate the specific nature of the con-
ditions under which IgA is capable of activating the alternative
pathway of complement. It also shows that pIgA has a higher
phlogogenic potential than does mIgA. The deposition of pIgA
in the mesangium and the activation of the alternative pathway
of complement, including the terminal sequence, are probably
crucial in the induction of the inflammatory lesions in the
glomeruli and the development of hematuria in IgAN.
Immunogenesis of IgA nephropathy
Mesangial deposits. The IgA deposited in the mesangium is
thought to be derived from the circulation, probably in the form
of circulating IgA-containing immune complexes. The recur-
rence of IgAN in approximately 50% of patients with IgAN who
receive renal allografts [20] indicates that the mesangial IgA
must be of host origin. Another observation that argues for the
host origin of mesangial IgA is the finding that mesangial IgA
deposits in kidneys inadvertently transplanted into recipients
who originally did not have IgA nephropathy disappear within 2
to 3 months [21]. The latter observation suggests that unless
IgA is continuously deposited in the mesangium, the mesangial
deposits disappear, possibly because of the solubilizing effect of
complement [221. The second reason to suspect that circulating
IgA complexes are responsible for the formation of mesangial
IgA deposits is the mesangial pattern per Se. This pattern is seen
frequently in experimental animals after antigen-antibody corn-
plexes have been given intravenously [23]. If IgA complexes are
circulating, deposition of these complexes also should occur at
sites other than the glomeruli. Such deposits have been re-
ported in the wall of cutaneous venules [24], and in blood
vessels of skeletal muscles [25].
5 Macromolecular IgA in blood. The presence of macromolec-
ular IgA in the circulation of patients with IgAN was first
documented by sucrose density gradient ultracentrifugation of
sera from patients with this disease [26]. Macromolecular IgA
was found in 73% of the patients. Its size varied between ilS
and l9S and it could bind secretory component. This IgA most
likely represents pIgA as such, or pIgA as part of an immune
complex. Control subjects and IgAN patients with infections
showed increases in the serum concentration of pIgA, but in the
patients with IgAN, the increase was greater and persisted
longer [27]. Others have reported that in children with IgAN,
episodes of macroscopic hematuria are associated with in-
creases of pIgA serum concentrations [28] and IgA immune
complexes [29]. During relapses associated with upper respira-
tory tract infections, the circulating IgA-bearing B-lymphocytes
from these children also produced more pIgA in vitro. These
rises were not seen in controls with upper respiratory tract
infections [28]. Other researchers have reported similar findings
[30].
The presence of elevated serum levels of pIgA during relapse
does not exclude the simultaneous presence of IgA immune
complexes in the circulation. Several techniques have been
developed to demonstrate circulating IgA immune complexes in
sera of patients with IgAN. In an assay developed by our group,
radiolabeled, low-avidity 1gM anti-IgA antibodies were used
that bind effectively to IgA covalently linked to Sepharose
beads [31]. Pre-incubation of sera from patients with Henoch-
SchOnlein purpura (HSP) or IgAN with these radiolabeled
anti-IgA antibodies reduced the amount of antibodies available
for binding to the IgA-Sepharose beads. The degree of inhibi-
tion of binding to IgA-Sepharose correlates linearly with the
amount of IgA aggregates or IgA immune complexes present in
the sample [31]. With this assay we were able to demonstrate
circulating IgA immune complexes in sera of patients with FISP
[31]. The potential overlap of values between HSP and control
sera disappeared if HSP serum was first precipitated with 3%
polyethyleneglycol (PEG). The strongest degree of inhibition
was obtained with the PEG precipitate. We subsequently
showed by sucrose density gradient ultracentrifugation that the
larger (> 19S) IgA-immune complexes were precipitated by
PEG. In 64% of cases, PEG-precipitable IgA immune com-
plexes were found in serum of patients with HSP (Table 3).
These IgA complexes could be detected only as long as new
purpuric lesions developed in the skin [32]. Sera from patients
with IgAN (64%) also have inhibitory activity. In the majority
of cases, the reactive material could not be precipitated with
PEG (Table 3). The macromolecular IgA in sera from patients
with IgAN usually has a size less than 19S. This IgA could
represent small IgA immune complexes, but it could just as well
represent pIgA, which is also detected in this assay (not
shown). Other methods have been developed to demonstrate
C3b or C3d in circulating macromolecular IgA. Solid-phase
conglutinin can bind to C3d bound to IgA, and if an anti-IgA
antibody is used as a probe, the C3d-IgA complex can be
detected. Using this technique, Coppo et al found 46% of
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patients with IgAN to be positive [331. A similar approach was
applied using Raji cells, which have C3d receptors (CR2). Using
this technique, Hall et a! found 68% of patients to be positive
[34]. Whatever technique is used to detect macromolecular IgA,
the highest percentage of positive results does not exceed 70%.
The explanation for the formation of mesangial IgA deposits in
patients without circulating IgA immune complexes could be
that these deposits are formed in situ.
The clearest distinction between pIgA and IgA immune
complexes could be made when antigen could be demonstrated
either complexed in the circulation or in the mesangial deposits.
The specificity of renal eluates binding to the original biopsy
and some other IgAN biopsies but not to normal glomeruli [35]
suggests that such antigens are present in the mesangial depos-
its. The presence of shared IgA idiotypes in serum and circu-
lating immune complexes suggests that the antigen responsible
for IgAN could be shared among patients with IgAN. Until
now, it has not been possible to identify unequivocally specific
antigens that are responsible for the formation of mesangial IgA
deposits in patients with IgAN. Several antigens have been
proposed, such as food antigens, viral antigens, and auto-
antigens [361.
Kinetics of IgA. Several studies have examined the origin and
kinetics of IgA and of pIgA. Of the 1400 mg of IgA produced
daily in the bone marrow, about 300 mg is pIgA [371. The IgA in
the circulation is mainly derived from the bone marrow [38].
Because pIgA has a shorter half-life than mIgA, the majority of
serum IgA is monomeric. The mucosal system, including the
respiratory, gastrointestinal, and genitourinary tract, produces
more than 3000 mg of IgA daily, Approximately 90% of the IgA
produced in the mucosal system is pigA. It is coupled to
secretory component and transported across epithelial cells of
the mucosa and secreted. In rodents, secretory component is
also present on hepatocytes. Due to its high affinity for secre-
tory component, circulating pIgA in these animals is taken up
and excreted efficiently in the bile. In humans, secretory
component cannot be detected on hepatocytes. The hepatic
uptake of human IgA is probably mediated by the asialoglyco-
protein receptor. IgA-immune complexes can be endocytosed
by Fca-receptors and C3 receptors (CR1) on Kupifer cells.
Mucosal origin of IgA. Mascart-Lemone et al recently found
that parenteral immunization of volunteers with tetanus toxoid
(TT) vaccine produces a polymeric and monomeric IgA anti-
body response [39]. At the peak of the response, pIgA ac-
counted for approximately one-half of the anti-TT serum activ-
ity. However, pIgA antibodies disappeared rapidly from the
serum over a few weeks, whereas the serum mIgA antibodies
persisted over a prolonged period. The rapid and strong pIgA
response also was found after parenteral and oral immunization
with typhoid vaccine [40]. Oral vaccination of volunteers with
cholera vaccine induces specific antibody-producing cells both
in the salivary glands and in peripheral blood [41]. This and
other observations in experimental animals suggest that a
common mucosal immune system exists [42j. After precursor
B-lymphocytes have been stimulated by antigen and helper
T-lymphocytes, these cells migrate via regional lymph nodes to
the circulation. The majority of these cells return to mucosal
sites [43]. It is pertinent to the patient presented here that rats
with experimental pyelonephritis not only secrete specific IgA
antibodies in their urine but also in their bronchial washings
[441. Some B-cells localize in the bone marrow and differentiate
into IgA-producing plasma cells.
Food antigens. Removal of the suspected food antigens from
the diet of patients with primary IgAN frequently lowers the
levels of circulating IgA immune complexes, but it does not
affect the clinical manifestations (or the progression) of lgAN as
was shown for patients receiving a gluten-free diet [45]. Patients
with gluten-sensitive enteropathy have been screened for the
presence of IgAN. The association occurs but is relatively rare
[461. The frequency of IgA antigliadin antibodies in primary
IgAN depends strongly on the technique used to detect these
antibodies. Compared with patients with other types of glomer-
ulonephritis, in patients with IgAN the frequency of IgA
anti-gliadin antibodies does not seem to be increased [46, 47].
Other food antigens have been implicated in the pathogenesis of
IgAN. Among them are casein, soybean protein, and rice
protein. These antigens have been detected by immunofluores-
cence in the mesangial deposits [481. Further studies are re-
quired to substantiate these findings.
Viral antigens. Viral antigens also have been implicated.
Cytomegalovirus (CMV) antigens recently have elicited great
interest. Gregory et al reported that CMV antigens could be
detected by immunofluorescence in the mesangial areas of IgA
deposition [49]. These experiments have been repeated by
numerous groups but the results could not be reproduced [50,
51]. A high incidence of CMV DNA was detected in kidneys of
patients with IgAN by the polymerase chain reaction (PCR)
[521. In view of the pitfalls involved in the quantitative use of
PCR, it would be encouraging if this finding was confirmed
independently.
Epstein-Barr viral (EBV) antigens also have been thought to
play a pathogenetic role [53]. Patients with IgAN more often
had antibodies directed against nuclear-associated antigens of
EBV than did controls. Evidence for mesangial deposition of
EBV antigens is not available. Hepatitis B viral (HBV) antigens
have been detected in the mesangium of patients with IgAN
from endemic areas [54]. It is unlikely that HBV antigens play
a pathogenetic role in other geographic areas [55].
Antigen-independent mechanisms. Antigen-independent
mechanisms also have been considered to explain the deposi-
tion of IgA in the mesangium. Monteiro et al found that IgA
eluted from renal biopsies was mainly polymeric, with an
isoelectric point between 4.5 and 5.6, in contrast to the p1
between 4.5 and 6.8 of normal serum IgA [561. It is not clear
how this restriction in electrical charge facilitates mesangial
deposition, as cationic rather than anionic charge of immune
complexes seems to play a role in this process [57]. Cederholm
and coworkers have suggested that collagen type iVa in the
mesangium interacts with circulating IgA; this interaction is
probably mediated by fIbronectin [58]. It has not been possible
using immuno-electron microscopy to demonstrate type-IV
collagen or fibronectin within the mesangial deposits [59]. We
have tried to detect fibronectin in the glomerular deposits in 9
renal biopsy specimens, and we also were unable to detect it
(unpublished observation). Sera from IgAN and AIDS patients
have high igA binding to collagen types II, III, and VI. Only
IgA from IgAN patients binds to collagen type V, which is not
fibronectin mediated and may reflect autoantibody formation
[60]. AIDS patients rarely develop IgAN, so the interaction
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between IgA and collagen probably is not an essential process
in the mesangial deposition of IgA in IgAN.
Ballardie and colleagues have suggested that IgA localizes in
the mesangium because patients with IgAN produce IgG auto-
antibodies with specificity for glomerular antigens [611. Others
have found that renal eluates from these patients do not react
with normal glomeruli [35]. Serum IgA antibodies directed
against human umbilical venous endothelium have been re-
ported in 24% of patients with IgAN [621. The nature of this
antigen and its presence in the mesangium have not yet been
established. The prevalence of antinuclear antibodies in sera of
patients with IgAN does not differ significantly from that in
controls [631. Matsiota et al have suggested that these patients
produce polyspecific autoantibodies that are not necessarily
related to the pathogenesis of the disease [64]. Sinico et al found
IgA rheumatoid factor in the sera of 52% of patients with IgAN
[651. The presence of these anti-IgG antibodies in the circula-
tion correlated with the presence of IgG in the mesangial
deposits. It was suggested in this study that IgG could be an
important factor in the formation of mesangial IgA-IgG depos-
its. The high serum levels of IgA, IgA rheumatoid factor, and
IgA immune complexes combined with the rare occurrence of
IgAN in AIDS patients [66, 67] indicates that other factors must
play a role in the process of mesangial deposition of IgA.
The increased levels of mIgA1, pIgA1, and IgA1-containing
immune complexes in the circulation [681 and the almost
exclusive deposition of the IgA1 subclass in the mesangium of
patients with IgAN [91 has stimulated numerous attempts at
establishing the site of IgA1 overproduction. Early studies have
shown that the number and the proportion of IgA-producing
cells in the mucosa of the jejunum do not differ from those of
healthy controls [69]. However, tonsils of patients with IgAN
contain more IgA- and pIgA-producing cells than do those of
controls [70, 71]. The high proportion of IgA1-producing cells in
tonsils [72] is consistent with the tonsils as a possible source of
increased IgA1 production in patients with IgAN. It is less clear
whether tonsilitis plays an important role in the majority of
patients with IgAN. It could be more important in children with
so-called synpharyngitic gross hematuria and be less significant
in adults, who frequently develop IgAN even after tonsillec-
tomy has been performed.
Under normal conditions, almost all IgA in the circulation is
produced in the bone marrow [38]. To determine the source of
the increased IgA1, Van den Wall Bake et al studied the bone
marrow of patients with IgAN [68]. U sing immunofluorescence,
we counted the number of IgA1- and IgA2-producing cells and
measured the production of IgA subclasses by culturing bone
marrow cells in vitro. An increased production of IgA1 was
found in patients with IgAN as compared with controls. These
results indicate that the increased serum levels of IgA1 in
patients with IgAN is caused by increased production of IgA1 in
the bone marrow. In a subsequent study, patients were immu-
nized with influenza virus vaccine to determine whether they
were hyperresponders. The specific anti-influenza response in
patients with IgAN was very similar to controls when 1gM, IgG,
and IgA2 responses were compared. However, the IgA1 re-
sponse was significantly higher in patients than in controls [73].
These data suggest that patients with IgAN are hyperre-
sponders exclusively for the IgA1 isotype. In children and
adults with recurrent gross hematuria, this IgA1 hyperresponse
is also expressed by overproduction of pIgA1. On the basis of
our studies, one can assume that deposition of pIgA1 in the
mesangium creates conditions favoring activation of the alter-
native pathway of complement and the terminal MAC. The
activation of the alternative pathway of complement probably
plays an essential role in the pathogenesis of IgAN. However,
the mechanism responsible for the mesangial deposition of IgA
is still unclear.
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I believe Dr.
Steven Emancipator might argue that reduced clearance of IgA
complexes is important in the pathogenesis of IgA nephropathy.
Would you comment on this argument?
Dn. VAN Es: It is my impression that Emancipator shares our
doubts on the role of defective clearance of IgA immune
complexes in IgAN patients [74]. The probes that have been
used to demonstrate defective clearance of circulating IgA
immune complexes are still controversial. Most studies have
used heat-damaged erythrocytes or IgG-sensitized erythro-
cytes. The removal of these cells is a splenic function [75, 76]
and not a function of hepatic phagocytes. Experimental studies
clearly have shown that preformed soluble immune complexes
are removed from the circulation primarily by Kupifer cells and
not by splenic macrophages [77]. Secretory IgA also has been
used as a probe, but it cannot be considered an analogue for
circulating IgA immune complexes [78]. Recently, studies have
been performed using cross-linked human polymeric IgA [79].
This study could not demonstrate a clearance defect in patients
wth IgAN. However, another study using mixed aggregates of
IgA and IgG found delayed clearance in IgAN patients [80]. On
the basis of these contradictory results, one cannot conclude
that a defect exists in the clearance of circulating IgA-immune
complexes in patients with IgAN.
DR. FRANCIS P. MULDOWNEY (Professor, Department of
Metabolism, St. Vincent's Hospital and University College,
Dublin, Ireland): If it can be accepted that corticosteroid
therapy is effective in IgA nephropathy, as today's patient
suggests, and if the prognosis is improved, especially when
therapy is commenced when GFR is above 70 ml/min, at what
point in the overall syndrome of "benign recurrent hematuria"
would you: (1) biopsy, and (2) start treatment? Our usual
practice would be to do neither unless there is hypertension,
albuminuria, or a decline in GFR.
Also, what is the role of routine antibiotic therapy in patients
in whom recurring upper respiratory infections are associated
with hematuria?
DR. VAN Es: In the United States, asymptomatic hematuria
usually is not an indication for a renal biopsy, whereas in
Europe it frequently is. Long-term followup data have taught us
that the majority of patients with IgA nephropathy have a slow
but steady loss of renal function over the course of twenty or
thirty years. Other causes for asymptomatic hematuria can be
transient, as in postinfectious glomerulonephritis; benign, as in
thin membrane disease; or slowly progressive, as in membran-
oproliferative glomerulonephritis. In practice, it is up to pa-
tients to decide whether they prefer to be informed more
accurately about the prognosis of their disease.
To demonstrate a beneficial effect of any drug, one must
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show that this drug favorably influences the natural course of
the disease. In an actuarial curve, about 1.5% of patients with
IgAN reach yearly terminal renal failure [101; this survival plot
illustrates the slow progression of this disease. To influence this
indolent course, corticosteroids probably would have to be
prescribed either chronically or intermittently. The long-term
disadvantages of this approach will probably exceed the poten-
tial long-term beneficial effects. The use of antibiotics is even
more controversial. Upper airway infections have been re-
ported to precede an exacerbation of IgAN. However, the
majority of our patients have microscopic hematuria without
exacerbations. Bacterial cultures from nose and throat do not
give any clues justifying the use of specific antibiotics. The
decreasing incidence of post-streptococcal glomerulonephritis
has been attributed to the wide use of antibiotics. A parallel
development has not been observed with respect to the inci-
dence of IgAN.
DR. JEROME P. KASSIRER (Editor-in-Chief, New Eneland
Journal of Medicine. Boston, Massachusetts): I am puzzled by
your hypothesis that the bone marrow is a continuous source of
IgA1. Does the production of IgA1 in the bone marrow continue
indefinitely without recurrent entry of lymphocytes? Lympho-
cytes don't live forever!
DR. VAN Es: B-lymphocytes continously migrate from the
bone marrow to Peyer's patches in the gut and to the respira-
tory tract, where they are exposed to antigens. They subse-
quently migrate to regional lymph nodes to transform into
IgA-containing blast cells. Via efferent lymphatic vessels and
the thoracic duct, they reach the blood stream, from which they
emerge at mucosal sites. The T-lymphocytes follow a similar
migration pattern. Some of the B-lymphocytes do not return at
a mucosal site but localize in bone marrow. Further stimulation
and differentiation of these B-cells depend on the help of
T-lymphocytes. It is generally assumed that specialized
T-helper cells are responsible for the switch from 1gM- or
IgG-producing cells to IgA-producing cells. The existence and
nature of these so-called "switch cells" in patients with IgAN
are still controversial. It is generally assumed that a continuous
influx of B- and T-lymphocytes into the bone marrow is
required to explain the persistent overproduction of IgA1 in
patients with IgAN. An increased helper/suppressor T-lympho-
cyte ratio has been reported by some [81, 821, but this finding
has not been confirmed by others [83, 84]. The immunologic
abnormality responsible for the dysregulation of IgA1 synthesis
in bone marrow is still unknown.
DR. YVES PIR50N (Associate Chief, Renal Unit, Clinical
University of St. Luc, Brussels, Belgium): You mentioned that
IgA deposits recur in the graft of approximately 50% of patients
with Berger' s disease but that the clinical disease develops in
only a small fraction of them. Would that mean that immuno-
suppressive therapy, if given very early, could slow the pro-
gression of the disease? Is the recurrence in the graft as
frequent when cyclosporine is used as with a conventional
immunosuppressive regimen?
DR. VAN Es: The recurrence of IgAN in renal allografts needs
to be defined. Mesangial IgA deposits have been reported in 17
of 32 patients with IgAN who had received renal transplants
[85]. The IgA deposits developed between 3 months and 4 years
after transplantation. The deposits persisted after they re-
curred. Five of these 17 patients had a normal urinalysis; the
remaining 12 developed minimal proteinuria and/or microscopic
hematuria. Declining renal function was not observed in this
study. Determination of progression by long-term followup is
complicated because the GFR of renal allografts declines faster,
independently of IgAN, than has been reported for the natural
course of IgAN. I know of no studies comparing the effect of
conventional immunosuppression with the effect of cyclospo-
rine on the recurrence of IgAN.
DR. ALEX M. DAVISON (Consultant Renal Physician, Depart-
ment of Renal Medicine, St. James's University Hospital,
Leeds, United Kingdom): In the pathogenesis of IgA nephrop-
athy, what is the mechanism of the production of hematuria
within 1 to 2 days of the development of a mucosal inflamma-
tion? Is there a significant number of patients in whom the
nephropathy appears to remit after 5 to 10 years? What is the
natural history of the mesangial IgA deposits?
DR. VAN Es: The relatively short latent period between
mucosal inflammation and the clinical exacerbation of IgAN
can only be explained by the development of antigenemia in
these patients, which leads to formation of immune complexes
with pre-existing IgA antibodies in the circulation. Spontaneous
remission has been reported in 30%—50% of Japanese children.
In adults, however, spontaneous remission after S to 10 years is
less common. On the basis of the fairly rapid disappearance of
mesangial IgA deposits from kidneys that have been trans-
planted into non-IgAN recipients, it has to be postulated that
IgA deposits in IgAN patients are formed continuously in the
mesangium.
DR. MICHEL OLMER (Chief, Nephrology Unit, Hôpital de Ia
Conception, Marseille, France): What is the determinant of the
IgA migration from the tonsils or other locations to the kidneys?
Also, is the pathogenesis identical in secondary IgA nephrop-
athy, especially in cirrhosis?
Da. VAN Es: IgA produced at mucosal sites probably reaches
the circulation in only minute quantities [86]. As I stated earlier,
the IgA deposited in the glomeruli is derived from the circula-
tion and most likely produced in the bone marrow [681. We have
not extensively analyzed the IgA subclasses in secondary
IgAN. The mesangial IgA deposits observed in patients with
alcoholic liver cirrhosis contain both subclasses of IgA. The
serum levels of IgA2 are elevated in these patients. Mesangial
IgA deposits are common in alcoholic liver cirrhosis, but overt
IgA nephropathy is unusual.
DR. MICHAEL H. RAMBAUSEK (Department of Nephrology,
University of Heidelberg, Heidelberg, Germany): Would you
speculate on the mechanisms underlying the different incidence
between mesangial IgA deposits in the general population (2%)
and clinically overt IgA glomerulonephritis (0.02%)?
DR. VAN Es: We know from animal experiments that several
factors can influence the development of glomerulonephritis:
the amount of immunoglobulin deposits, the capacity to acti-
vate the complement sequence including the membrane attack
complex (MAC); and the influx of monocytes. Non-immuno-
logic factors are the intraglomerular pressure and the activation
of the coagulation and fibrinolytic system. Individuals can differ
in the responsiveness of their mediator systems.
DR. RAMBAUSEK: Why does phenytoin therapy successfully
lower IgA serum levels yet have no influence on the progression
of IgA nephropathy?
DR. VAN Es: We do not know why the reduction in IgA serum
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levels by phenytoin has no beneficial effect on IgAN. One
explanation would be that phenytoin does not influence the titer
of nephritogenic IgA antibodies. We have no information on the
nature of such antibodies, however. Such a role has been
postulated for polymeric IgA antibodies, for IgA rheumatoid
factor, and for IgA immune complexes. Patients with acquired
immunodeficiency syndrome fulfill all three conditions but, as I
pointed out, these patients rarely develop IgAN [67].
DR. ARTURO BORSATTI (Professor of Nephrology, Institute
of Internal Medicine, University of Padova, Padova, Italy):
The clinical picture of IgA nephropathy can be quite different,
but most probably the underlying pathogenetic mechanism is
the same. What determines the clinical course of the disease? Is
it the quantity of IgA produced?
DR. VAN Es; The quantity of IgA deposited in the mesan-
gium, in particular the amount of polymeric IgA deposited, can
influence the degree of complement activation and the chemo-
attraction of monocytes. Host factors are probably also impor-
tant. The local inflammatory reaction and the local generation
of angiotensin II can lead to various degrees of proliferation of
mesangial cells in different individuals. The intraglomerular
pressure also can contribute to the damage inflicted on the
glomerular capillaries. It would be interesting to know why the
severity of IgAN differs among different geographic areas.
DR. JOHN F. DoNoHoE (Consultant Nephrolo gist, Depart-
ment of Nephrology, Beaumont Hospital, Dublin, Ireland): Are
IgA nephropathy (Berger's disease) and Henoch-Schonlein
purpura simply part of the same overall spectrum of IgA
nephritis? Can they switch from one to the other? For example,
can an originally classic IgA nephropathy present years later as
a classic, acute Henoch-Schonlein purpura?
DR. VAN Es; An extensive literature exists on the occurrence
of IgAN and Henoch-SchOnlein purpura (HSP) within one
family. Even more interesting is the observation of IgAN and
HSP in identical twins, which suggests that the two diseases
might be strongly related but also that acquired factors might
influence the severity of the disease and the development of
systemic manifestations. There have been descriptions of chil-
dren who developed IgAN after having HSP. I am not aware of
the reverse order.
DR. ANDREW REES (Professor of Nephrology, Royal Post-
graduate Medical School, London, United Kingdom): You
have shown very clearly that mesangial deposition of IgG is not
needed for complement deposition in IgA nephropathy and, as
today's patient indicates, IgG deposition is not necessary for
acute injury to occur in this disease. Nevertheless, IgG is found
in as many as 70% of patients. Why do you think it is there?
Specifically, what is the role of IgG antimesangial autoantibod-
ies described by Ballardie and colleagues [61]?
DR. VAN Es; The possible role of IgG in the mesangial
deposits can be manifold. It could serve as the antigen for IgA
rheumatoid factor, which is present in about 30% of the cases
[65]. It could be deposited because it recognizes the same
antigen as the IgA antibodies. Studies also have demonstrated
in sera of patients with IgAN IgG antibodies that are directed
against IgA [87]. Antibodies directed against endothelial cells
isolated from umbilical cord veins also have been reported in
sera of 24% of patients with IgAN [62]. Because these endo-
thelial cells carry ABO, HLA, and other allo-antigens on their
cell surface, rigorous typing of these cells and use of proper
controls is required to demonstrate the true autoimmune char-
acter of these antibodies. Earlier studies demonstrated that
eluates from IgAN kidneys react with the mesangial area of the
same patient but not with the mesangium of normal kidneys and
only with one-third of biopsies from IgAN patients. In Ba!-
lardie's study, the IgG antibodies reacted with 3 components
isolated from a homogenate of normal glomeruli [61]. Positive
sera were found in 30% of patients. Further studies are required
to confirm these findings.
DR. GIU5EPPE REMUZZI (Head, Laboratory of Kidney Dis-
ease, Mario Negri Institute, Bergamo, Italy); As for the possi-
bility of finding a marker of disease progression, researchers in
Dr. Kishimoto's group have documented that patients with IgA
nephropathy who have continuously elevated urinary IL-6
activity also have histologic signs of renal disease progression,
whereas those with undetectable urinary IL-6 activity have a
benign course with histologic improvement of IgA nephropathy
[88]. Would you please comment?
DR. VAN Es: It certainly is an interesting observation. We
have tried to repeat this study. In contrast to 11-6 concentrations
in the urine of transplant recipients, we found marginal eleva-
tions of IL-6 in the urine of patients with IgAN. On the basis of
the reported production of IL-6 by mesangial cells, it could be
expected that patients with mesangial proliferation would ex-
crete more IL-6 in their urine. We were unable to confirm this
finding, however.
DR. NIcoLAos E. MADIA5 (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Were
the levels of your assays obtained during periods of activity or
quiescence of the disease? Did you imply that most of the
difference in the geographic distribution of the disease can be
explained on the basis of screening programs that some coun-
tries have? If not, what might be the basis for differences in the
geographic distribution of IgA nephropathy?
DR. VAN Es: It is difficult to differentiate between activity or
quiescence of the disease in our patients. In contrast to patients
in the south of Europe and children, our patients have a more
indolent course. Davin et al showed in children that IgA
immune complexes are elevated during episodes of gross he-
maturia, and are absent or significantly lower during quiescence
[29]. As to the geographic differences, it is certainly my
impression that blacks have a lower incidence of IgAN. But I
am also convinced that the existing differences in the indication
for a renal biopsy must have a strong effect on the reported
prevalence of IgAN in various countries.
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